Xeloda as first-line therapy of metastatic colorectal cancer-our experience
BACKGROUND: Results of phase III clinical studies comparing efficacy of Xeloda vs. standard 5-FU/FA protocols as first line therapy of metastatic colorectal carcinoma (MCRC), have shown better efficacy of Xeloda, with less toxic adverse effects, apart from handfoot syndrome. METHODS: From January 20...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Institute of Oncology, Sremska Kamenica, Serbia
2002-01-01
|
| Series: | Archive of Oncology |
| Subjects: | |
| Online Access: | http://www.doiserbia.nb.rs/img/doi/0354-7310/2002/0354-73100204249K.pdf |
| _version_ | 1818833143571939328 |
|---|---|
| author | Kovčin Vladimir Ješić Rada Krivokapić Zoran V. Andrić Zoran Pavlović Aleksandra |
| author_facet | Kovčin Vladimir Ješić Rada Krivokapić Zoran V. Andrić Zoran Pavlović Aleksandra |
| author_sort | Kovčin Vladimir |
| collection | DOAJ |
| description | BACKGROUND: Results of phase III clinical studies comparing efficacy of Xeloda vs. standard 5-FU/FA protocols as first line therapy of metastatic colorectal carcinoma (MCRC), have shown better efficacy of Xeloda, with less toxic adverse effects, apart from handfoot syndrome. METHODS: From January 2000 to May 2001 the study enrolled 54 patients with MCRC, 38 males and 16 females, aged 30-78 years. All patients had metastatic diseases. In 33 the primary tumor was in colon, in 21 in rectum. All patients received Xeloda 2500 mg/m2/day in two daily doses, during 14 days followed by 7 days of pause. Dose intensity was 88,79% +/- 9,2. For efficacy evaluation the WHO criteria and tumor markers CEA and CA 19-9 were used. RESULTS: Overall response rate was 47%, with 13% complete responses, 34% partial responses 38% stable disease and 15% disease progression. No significant difference was found between patients with regard to localization of primary tumor (colon or rectum). There was no significant difference in response rate when compared 27 patients with adverse events of capecitabine ('hand and foot' syndrome and diarrhea) and those without them. Response rate in a subgroup of 21 evaluable (out of 29) patients with initial signs of liver dysfunction was worse (p<0.005) in comparison with patients with normal liver function. Most frequent adverse events were 'hand and foot' syndrome (52%) and diarrhea (24%), or both (14%). Other adverse events, up to grade 2 toxicity, were sporadically reported; however, hematological toxicity was significantly more common in a subgroup of patients with compromised liver function (p<0.007). CONCLUSION: This study has shown that Xeloda is a good monotherapy choice, with high response rate as first line therapy of metastatic CRC. Adverse events do not influence response. Liver dysfunction is a poor prognostic parameter. Therapy with Xeloda is convenient and relatively safe in patients with liver dysfunction, where administration of other cytotoxic agents is not possible. |
| first_indexed | 2024-12-19T02:14:14Z |
| format | Article |
| id | doaj.art-da70868540664f2795150181bdefc9ce |
| institution | Directory Open Access Journal |
| issn | 0354-7310 |
| language | English |
| last_indexed | 2024-12-19T02:14:14Z |
| publishDate | 2002-01-01 |
| publisher | Institute of Oncology, Sremska Kamenica, Serbia |
| record_format | Article |
| series | Archive of Oncology |
| spelling | doaj.art-da70868540664f2795150181bdefc9ce2022-12-21T20:40:30ZengInstitute of Oncology, Sremska Kamenica, SerbiaArchive of Oncology0354-73102002-01-0110424925210.2298/AOO0204249KXeloda as first-line therapy of metastatic colorectal cancer-our experienceKovčin VladimirJešić RadaKrivokapić Zoran V.Andrić ZoranPavlović AleksandraBACKGROUND: Results of phase III clinical studies comparing efficacy of Xeloda vs. standard 5-FU/FA protocols as first line therapy of metastatic colorectal carcinoma (MCRC), have shown better efficacy of Xeloda, with less toxic adverse effects, apart from handfoot syndrome. METHODS: From January 2000 to May 2001 the study enrolled 54 patients with MCRC, 38 males and 16 females, aged 30-78 years. All patients had metastatic diseases. In 33 the primary tumor was in colon, in 21 in rectum. All patients received Xeloda 2500 mg/m2/day in two daily doses, during 14 days followed by 7 days of pause. Dose intensity was 88,79% +/- 9,2. For efficacy evaluation the WHO criteria and tumor markers CEA and CA 19-9 were used. RESULTS: Overall response rate was 47%, with 13% complete responses, 34% partial responses 38% stable disease and 15% disease progression. No significant difference was found between patients with regard to localization of primary tumor (colon or rectum). There was no significant difference in response rate when compared 27 patients with adverse events of capecitabine ('hand and foot' syndrome and diarrhea) and those without them. Response rate in a subgroup of 21 evaluable (out of 29) patients with initial signs of liver dysfunction was worse (p<0.005) in comparison with patients with normal liver function. Most frequent adverse events were 'hand and foot' syndrome (52%) and diarrhea (24%), or both (14%). Other adverse events, up to grade 2 toxicity, were sporadically reported; however, hematological toxicity was significantly more common in a subgroup of patients with compromised liver function (p<0.007). CONCLUSION: This study has shown that Xeloda is a good monotherapy choice, with high response rate as first line therapy of metastatic CRC. Adverse events do not influence response. Liver dysfunction is a poor prognostic parameter. Therapy with Xeloda is convenient and relatively safe in patients with liver dysfunction, where administration of other cytotoxic agents is not possible.http://www.doiserbia.nb.rs/img/doi/0354-7310/2002/0354-73100204249K.pdfColorectal neoplasmsantimetabolitesantineoplasticcombined chemotherapy protocolsneoplasm metastasistreatment outcome |
| spellingShingle | Kovčin Vladimir Ješić Rada Krivokapić Zoran V. Andrić Zoran Pavlović Aleksandra Xeloda as first-line therapy of metastatic colorectal cancer-our experience Archive of Oncology Colorectal neoplasms antimetabolites antineoplastic combined chemotherapy protocols neoplasm metastasis treatment outcome |
| title | Xeloda as first-line therapy of metastatic colorectal cancer-our experience |
| title_full | Xeloda as first-line therapy of metastatic colorectal cancer-our experience |
| title_fullStr | Xeloda as first-line therapy of metastatic colorectal cancer-our experience |
| title_full_unstemmed | Xeloda as first-line therapy of metastatic colorectal cancer-our experience |
| title_short | Xeloda as first-line therapy of metastatic colorectal cancer-our experience |
| title_sort | xeloda as first line therapy of metastatic colorectal cancer our experience |
| topic | Colorectal neoplasms antimetabolites antineoplastic combined chemotherapy protocols neoplasm metastasis treatment outcome |
| url | http://www.doiserbia.nb.rs/img/doi/0354-7310/2002/0354-73100204249K.pdf |
| work_keys_str_mv | AT kovcinvladimir xelodaasfirstlinetherapyofmetastaticcolorectalcancerourexperience AT jesicrada xelodaasfirstlinetherapyofmetastaticcolorectalcancerourexperience AT krivokapiczoranv xelodaasfirstlinetherapyofmetastaticcolorectalcancerourexperience AT andriczoran xelodaasfirstlinetherapyofmetastaticcolorectalcancerourexperience AT pavlovicaleksandra xelodaasfirstlinetherapyofmetastaticcolorectalcancerourexperience |